The use of Akatinol Memantine in the treatment of gait disturbances in Parkinson’s disease

Miliukhina I.V.; Gracheva E.V.

doi:https://doi.org/10.17116/jnevro202012007127

Miliukhina I.V.

Institute of Experimental Medicine;
Pavlov First Saint Petersburg State Medical University

Gracheva E.V.

Institute of Experimental Medicine

The use of Akatinol Memantine in the treatment of gait disturbances in Parkinson’s disease

Authors:

Miliukhina I.V., Gracheva E.V.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2020;120(8): 27‑33

DOI: 10.17116/jnevro202012007127

Read: 8963 times

Download PDF (RU)

Contact the author

Table of contents

To cite this article:

Miliukhina IV, Gracheva EV. The use of Akatinol Memantine in the treatment of gait disturbances in Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2020;120(8):27‑33. (In Russ.)
https://doi.org/10.17116/jnevro202012007127

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова (S.S. Korsakov Journal of Neurology and Psychiatry)

Использование инфографики авторами научных работ

Close metadata

Abstract:

OBJECTIVE

To assess the efficacy of memantine hydrochloride in the treatment of GD in PD patients.

MATERIALS AND METHODS

Patients of the main group (n=30) received memantine hydrochloride (akatinol memantine) in a dose of 20 mg/day for 3 months in addition to antiparkinsonian therapy. Patients of the comparison group (n=25) received only antiparkinsonian drugs. Cognitive rating scales and computerized gait assessment protocol were performed in both groups twice in 3 months interval in order to examine cognitive deficit and gait parameters.

RESULTS

The increase in MMSE scores, improvement in gait cycle phases ratio and increase of cadence according to computerized gait analysis were observed in the main group compared to the comparison group.

CONCLUSION

The improvement in gait achieved during the study confirms that the treatment of cortical gait disturbances in patients with PD using memantine hydrochloride is a promising area of therapy.

Keywords:

gait disturbance

Parkinson’s disease

cortical gait control

memantine hydrochloride

akatinol

Authors:

Miliukhina I.V.

Institute of Experimental Medicine;
Pavlov First Saint Petersburg State Medical University

Gracheva E.V.

Institute of Experimental Medicine

Received:

18.05.2020

Accepted:

23.07.2020

Close metadata

References:

Stegemöller EL, Wilson JP, Hazamy A, Shelley MC, Okun MS, Altmann LJ, Hass CJ. Associations between cognitive and gait performance during single- and dual-task walking in people with Parkinson disease. Phys Ther. 2014;94(6):757-766. https://doi.org/10.2522/ptj.20130251
Miliukhina IV, Gracheva EV. Modern views on gait impairment in Parkinson`s disease and its correction. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2018;118(6):96‐101. (In Russ.). https://doi.org/10.17116/jnevro20181186196
Postuma RB, Berg D, Stern M, Poewe W, Olanow CW, Oertel W, Obeso J, Marek K, Litvan I, Lang AE, Halliday G, Goetz CG, Gasser T, Dubois B, Chan P, Bloem BR, Adler CH, Deuschl G. MDS clinical diagnostic criteria for Parkinson’s disease. Movement Disorders. 2015;30(12):1591-1601. https://doi.org/10.1002/mds.26424
Hanakawa T1, Fukuyama H, Akiguchi I, Kato M, Kimura J, Shibasaki H. Mechanisms underlying gait disturbance in Parkinson’s disease: a single photon emission computed tomography study. Brain. 1999;122(7):1271-1282. https://doi.org/10.1093/brain/122.7.1271
Moreau C, Delval A, Tiffreau V, Defebvre L, Dujardin K, Duhamel A, Petyt G, Hossein-Foucher C, Blum D, Sablonnière B, Schraen S, Allorge D, Destée A, Bordet R, Devos D. Memantine for axial signs in Parkinson’s disease: a randomised, double-blind, placebo-controlled pilot study. J Neurol Neurosurg Psychiatry. 2013;84(5):552-555. https://doi.org/10.1136/jnnp-2012-303182
Henderson EJ, Lord SR, Brodie MA, Gaunt DM, Lawrence AD, Close JC, Whone AL, Ben-Shlomo Y. Rivastigmine for gait stability in patients with Parkinson`s disease (ReSPonD): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Neurol. 2016;15(3):249-258. https://doi.org/10.1016/S1474-4422(15)00389-0
Meng YH, Wang PP, Song YX, Wang JH. Cholinesterase inhibitors and memantine for Parkinson’s disease dementia and Lewy body dementia: A meta-analysis. Experimental and therapeutic medicine. 2019;17(3):1611-1624. https://doi.org/10.3892/etm.2018.7129
Wictorin K, Widner H. Memantine and reduced time with dyskinesia in Parkinson`s Disease. Acta Neurol Scand. 2016;133(5):355-360. https://doi.org/10.1111/ane.12468
Beauchet O, Allali G, Launay C, Fantino B, Annweiler C. Does memantine improve the gait of individuals with Alzheimer`s disease? J Am Geriatr Soc. 2011;59(11):2181-2182. https://doi.org/10.1111/j.1532-5415.2011.03648.x
Hoops S, Nazem S, Siderowf AD, Duda JE, Xie SX, Stern MB, Weintraub D. Validity of the MoCA and MMSE in the detection of MCI and dementia in Parkinson disease. Neurology. 2009;73(21):1738-1745. https://doi.org/10.1212/WNL.0b013e3181c34b47
Aarsland D, Brønnick K, Fladby T. Mild cognitive impairment in Parkinson’s disease. Current Neurology and Neuroscience Reports. 2011;11(4):371-378. https://doi.org/10.1007/s11910-011-0203-1
Cosgrove J, Alty JE, Jamieson S. Cognitive impairment in Parkinson’s disease. Postgraduate Medical Journal. 2015;91(1074):212-220. https://doi.org/10.1136/postgradmedj-2015-133247
Hui-Fu Wang, Jin-Tai Yu, Shao-Wen Tang, Teng Jiang, Chen-Chen Tan, Xiang-Fei Meng, Chong Wang, Meng-Shan Tan, Lan Tan Efficacy and safety of cholinesterase inhibitors and memantine in cognitive impairment in Parkinson’s disease, Parkinson’s diseasedementia, and dementia with Lewy bodies: systematic review with meta-analysis and trial sequential analysis. Journal of Neurology, Neurosurgery, Psychiatry. 2015;86:135-43. https://doi.org/10.1136/jnnp-2014-307659
Levin OS, Yunishchenko NA, Dudarova MA. Efficacy of Akatinol Memantine in Moderate Cognitive Impairments. Neuroscience and Behavioral Physiology. 2010;40:926-933. https://doi.org/10.1007/s11055-010-9347-8